Aclasta: Zolendronic acid for Osteoporosis

Aclasta is an Osteoporosis drug sold in Europe. In the United states it is distributed under the name Reclast. If you wish to read the pages about the USA form, just click on Reclast

Both of these drugs are prescription forms of zoledronic acid. Like all forms of zolendronic acid, you take this drug only once a year. It is given by an infusion. And this is done right in your doctor's office.

This is what many people really like about this Osteoporosis treatment. It means they only need to go to their health care provider's office once each year for their Osteoporosis treatment. Many people find it a real help not to have to worry about remembering to take a daily or a weekly pill. There is nothing to remember with this drug - except to keep your annual appointment. 

But if you are considering taking it, you will want to know a bit more about this particular Osteoporosis drug. . You especially want to find out if there are things that could pose a problem for you.

Novartis is the company that manufactures Aclasta

And Novartis is one of the largest pharmaceutical companies in the world.The drug received its FDA approval after a three year study called Pivotal Fracture Trial  . This trial showed that the drug increased bone strength and it reduced fractures of the hip, spine and other areas prone to fracture such as your wrist, arm, leg or rib.

They claim this treament is  the only treatment that has been demonstrated to reduce fractures at ALL those key sites!

You may want to know that in May 2007 the New England Journal of Medicine stated that  a study involving more than 7,700 women showed that treatment with this drug reduced the risk of spine fractures by 70% and hip fractures by 41%.

The reduction in spine fractures for the three years of the study was as follows: 60% in year one; 71% in year two and 70% in year three.  Again, those are significant numbers! - especially when we consider that bone loss in the spine can lead to kyphosis or dowagers hump - a difficult and unsightly condition.

To read more about this medication and/or to print out material to take with your to your health care provider go to Aclasta, Reclast  Research Studies

NOTE: A spokesperson for Novatis said of the drug: "(It) has shown significant efficacy in protecting women against fractures in all the common osteoporotic fracture sites, while demonstrating a favorable safety profile, It is our hope that this innovative once-yearly dosing regimen will have a positive impact on the management of this potentially devastating condition."

Novartis says that this medication:

   "is indicated for treatment of osteoporosis in postmenopausal women. In patients with a recent low-trauma hip fracture," It "reduces the incidence of new clinical fractures". And it:

  • "is indicated for treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture."
  • "is indicated for treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in postmenopausal women and in men with increased risk of fracture"
  • .
  • and finally, "Aclasta is indicated for the treatment of Paget's disease of the bone."

Many in the health care community believe that once a year infusions are an effective remedy for the main problem with daily, weekly or monthly medications. The problem with daily or even monthly medications is that many people just stop taking the medications for Osteopenia and Osteoporosis! (This failure to take one's medication called 'non-compliance' bythe medical community and non-compliance with pills for bone loss is high.)

Side effects Since this drug is sold under various names in different countries, the same side effects would apply  under its other name, Reclast. In fact, if you live in the United States, the Novartis site directs your to a  page about Reclast.

Novartis is careful to mention the possibility of Osetonecrosis with any of the bisphosphonates. They also state:

"Disturbances of mineral metabolism must be treated before starting therapy. Patients must be adequately supplemented with calcium and vitamin D. A single dose of Aclasta should not exceed 5 mg and infusion time should be no less than 15 minutes."

A study published in March of 2013, showed more serious side effects: Acute kidney injury. You can read a summary of that study by clicking this link to the Journal of Oncology Practice.

If you want to read about other potential side effects and a list of conditions that would preclude using this drug go to: this page on the Osteopenia3 site and scroll down to Aclasta, Reclast Side Effects

Other medications for low bone density can be at Osteopenia and Osteoporosis medications

If you are interested in learning about the natural treatments for building stronger bones, go to Natural Osteopenia, Osteoporosis Treatments

NOTE: This web site offers science based information, not medical advice. For medical advice you need to consult a licensed medical practitioner.

I have a FREE monthly newsletter with updates about Osteopenia and Osteoporosis treatments. It also offers encouragement for women and men with the condition. Click here to subscribe toOsteopenia3 updates newsletter


SPECIAL NOTE: If you have used Aclasta and would like to leave a comment about your experience, please use the Testimonial form below.

Have you experience with this?

Do you have experience with this? Please share it!

[ ? ]

Upload 1-4 Pictures or Graphics (optional)[ ? ]


Click here to upload more images (optional)

Author Information (optional)

To receive credit as the author, enter your information below.

(first or full name)

(e.g., City, State, Country)

Submit Your Contribution

 submission guidelines.

(You can preview and edit on the next page)

What Other Visitors Have Said

Click below to see contributions from other visitors to this page...

Aclasta reaction Not rated yet
I had aclasta on a Tuesday afternoon that night I started shaking and felt like I had been transported to the Antartic. Muscle pain in the back and legs …

Click here to write your own.